The U.S. Food and Drug Administration (FDA) on June 22 approved Kengreal (cangrelor) for use in patients undergoing percutaneous coronary intervention to reduce thrombotic events. The approval is based on the results of the CHAMPION-PHOENIX trial – presented at ACC.13 by Deepak L. Bhatt, MD, MPH, FACC, member of the ACC’s Board of Trustees  – which showed that cangrelor reduced the risk of periprocedural complications by 22 percent with no significant increase in bleeding risk. An FDA advisory committee voted in favor of the drug’s approval in April of this year.

Read the FDA’s announcement. 

Keywords: Adenosine Monophosphate, Advisory Committees, Drug Approval, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Thrombosis, United States Food and Drug Administration

< Back to Listings